1. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †
- Author
-
Clement, PM, Gauler, T, Machiels, JP, Haddad, RI, Fayette, J, Licitra, LF, Tahara, M, Cohen, EEW, Cupissol, D, Grau, JJ, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, del Campo, JM, Cong, XJ, Ehrnrooth, E, and Vermorken, JB
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Dental/Oral and Craniofacial Disease ,Cancer ,Clinical Trials and Supportive Activities ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Afatinib ,Aged ,Aged ,80 and over ,Antineoplastic Combined Chemotherapy Protocols ,Carcinoma ,Squamous Cell ,Disease-Free Survival ,Female ,Head and Neck Neoplasms ,Humans ,Male ,Methotrexate ,Neoplasm Metastasis ,Neoplasm Recurrence ,Local ,Platinum ,Quinazolines ,Squamous Cell Carcinoma of Head and Neck ,Treatment Outcome ,LUX-H&N 1 investigators ,HNSCC ,afatinib ,methotrexate ,older ,phase III ,second-line ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundIn the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and
- Published
- 2016